The effect of artificial lipid envelopment of Adenovirus 5 (Ad5) on liver de-targeting and hepatotoxicity

Biomaterials

Volumn 34, Issue 4, 2013, Pages 1354-1363

  Yilmazer, Açelya ^a   Al Jamal, Wafa' T ^a   Van den Bossche, Jeroen ^a   Kostarelos, Kostas ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Blood factors; Gene therapy; Liposome; Targeting; Toxicity

Indexed keywords

ARTIFICIAL LIPID BILAYERS; BALB/C MICE; BLOOD COAGULATION; BLOOD COMPONENT; CATIONIC LIPIDS; CULTURED CELL; HEPATOCYTES; HEPATOTOXICITY; HUMAN ADENOVIRUS; IMMUNOGENICITY; IN-VITRO; INTRAVENOUS ADMINISTRATION; REAL-TIME PCR; RED BLOOD CELL; SERUM LEVELS; TARGETING; TRANSGENE EXPRESSION; VIRAL CAPSIDS; VIRAL PARTICLES;

BLOOD; GENE THERAPY; LIPOSOMES; POLYMERASE CHAIN REACTION; TOXICITY; VIRUSES;

LIPID BILAYERS;

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BLOOD CLOTTING FACTOR; CHOLESTEROL; CHOLESTEROL HYDROGEN SUCCINATE; DIOLEOYLPHOSPHOETHANOLAMINE; LIPID; PHOSPHOLIPID DERIVATIVE; UNCLASSIFIED DRUG;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD COMPONENT; CELL CULTURE; CELL STRAIN HEPG2; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID BILAYER; LIPID MEMBRANE; LIVER; LIVER CELL; LIVER HISTOLOGY; LIVER TOXICITY; LUNG; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; VIRUS STRAIN;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; DNA, VIRAL; GENE TARGETING; GENETIC VECTORS; HUMANS; LIVER; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C;

HUMAN ADENOVIRUS TYPE 5; MIRIDAE; MURINAE; MUS;

EID: 84870355223     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.10.053     Document Type: Article

References (46)

1. Liu Q., Muruve D.A. Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther 2003, 10:935-940.
2. Reid T., Warren R., Kirn D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther 2002, 9:979-986.
3. Shayakhmetov D. Virus infection recognition and early innate responses to non-enveloped viral vectors. Viruses 2010, 2:244-261.
4. Raper S.E., Chirmule N., Lee F.S., Wivel N.A., Bagg A., Gao G.-p., et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003, 80:148-158.
5. Huang X., Yang Y. Innate immune recognition of viruses and viral vectors. Hum Gene Ther 2009, 20:293-301.
6. Kreppel F., Kochanek S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther 2007, 16:16-29.
7. Wu T.-L., Ertl H.C.J. Immune barriers to successful gene therapy. Trends Mol Med 2009, 15:32-39.
8. Waddington S.N., McVey J.H., Bhella D., Parker A.L., Barker K., Atoda H., et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008, 132:397-409.
9. Lieber A., He C.Y., Meuse L., Schowalter D., Kirillova I., Winther B., et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 1997, 71:8798-8807.
10. Alemany R., Suzuki K., Curiel D.T. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 2000, 81:2605-2609.
11. Shashkova E.V., Doronin K., Senac J.S., Barry M.A. Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus. Cancer Res 2008, 68:5896-5904.
12. Worgall S., Wolff G., Falck-Pedersen E., Crystal R.G. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997, 8:37-44.
13. Koizumi N., Yamaguchi T., Kawabata K., Sakurai F., Sasaki T., Watanabe Y., et al. Fiber-modified adenovirus vectors decrease liver toxicity through reduced IL-6 production. J Immunol 2007, 178:1767-1773.
14. Tao N., Gao G.-P., Parr M., Johnston J., Baradet T., Wilson J.M., et al. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 2001, 3:28-35.
15. Kalyuzhniy O., Di Paolo N.C., Silvestry M., Hofherr S.E., Barry M.A., Stewart P.L., et al. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci U S A 2008, 105:5483-5488.
16. Parker A.L., Waddington S.N., Nicol C.G., Shayakhmetov D.M., Buckley S.M., Denby L., et al. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 2006, 108:2554-2561.
17. Shayakhmetov D.M., Gaggar A., Ni S., Li Z.-Y., Lieber A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 2005, 79:7478-7491.
18. Singh R., Al-Jamal K.T., Lacerda L., Kostarelos K. Nanoengineering artificial lipid envelopes around adenovirus by self-assembly. ACS Nano 2008, 2:1040-1050.
19. Singh R., Tian B., Kostarelos K. Artificial envelopment of nonenveloped viruses: enhancing adenovirus tumor targeting in vivo. FASEB J 2008, 22:3389-3402.
20. Van den Bossche J., Al-Jamal W.T., Yilmazer A., Bizzarri E., Tian B., Kostarelos K. Intracellular trafficking and gene expression of pH-sensitive, artificially enveloped adenoviruses in vitro and in vivo. Biomaterials 2011, 32:3085-3093.
21. Green N.K., Herbert C.W., Hale S.J., Hale A.B., Mautner V., Harkins R., et al. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther 2004, 11:1256-1263.
22. Waddington S.N., Parker A.L., Havenga M., Nicklin S.A., Buckley S.M.K., McVey J.H., et al. Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. J Virol 2007, 81:9568-9571.
23. Koizumi N., Mizuguchi H., Sakurai F., Yamaguchi T., Watanabe Y., Hayakawa T. Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and {alpha}v integrin-binding ablation. J Virol 2003, 77:13062-13072.
24. ten Hagen T.L.M., Van Vianen W., Bakker-Woudenberg I.A.J.M. Isolation and characterization of murine Kupffer cells and splenic macrophages. J Immunol Methods 1996, 193:81-91.
25. Baker A.H., McVey J.H., Waddington S.N., Di Paolo N.C., Shayakhmetov D.M. The influence of blood on in vivo adenovirus bio-distribution and transduction. Mol Ther 2007, 15:1410-1416.
26. Carlisle R.C., Di Y., Cerny A.M., Sonnen A.F.P., Sim R.B., Green N.K., et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting coxsackie virus-adenovirus receptor and complement receptor 1. Blood 2009, 113:1909-1918.
27. Di Paolo N.C., van Rooijen N., Shayakhmetov D.M. Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver. Mol Ther 2009, 17:675-684.
28. Callahan S.M., Ming X., Lu S.K., Brunner L.J., Croyle M.A. Considerations for use of recombinant adenoviral vectors: dose effect on hepatic cytochromes P450. J Pharmacol Exp Ther 2005, 312:492-501.
29. Sharma A., Bangari D.S., Tandon M., Pandey A., HogenEsch H., Mittal S.K. Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology 2009, 386:44-54.
30. Hartman Z.C., Appledorn D.M., Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 2008, 132:1-14.
31. Wonganan P., Clemens C.C., Brasky K., Pastore L., Croyle M.A. Species differences in the pharmacology and toxicology of PEGylated helper-dependent adenovirus. Mol Pharm 2008, 8:78-92.
32. Zaiss A.K., Machado H.B., Herschman H.R. The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem 2009, 108:778-790.
33. Alba R., Bradshaw A.C., Coughlan L., Denby L., McDonald R.A., Waddington S.N., et al. Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 2010, 116:2656-2664.
34. Hofherr S.E., Shashkova E.V., Weaver E.A., Khare R., Barry M.A. Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol Ther 2008, 16:1276-1282.
35. Zwaal R.F.A., Comfurius P., Bevers E.M. Lipid-protein interactions in blood coagulation. Biochim Biophys Acta 1998, 1376:433-453.
36. Lyons M., Onion D., Green N.K., Aslan K., Rajaratnam R., Bazan-Peregrino M., et al. Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther 2006, 14:118-128.
37. Song Y.K., Liu F., Liu D. Enhanced gene expression in mouse lung by prolonging the retention time of intravenously injected plasmid DNA. Gene Ther 1998, 5:1531-1537.
38. Koizumi N., Kawabata K., Sakurai F., Watanabe Y., Hayakawa T., Mizuguchi H. Modified adenoviral vectors ablated for coxsackie virus adenovirus receptor, alphav integrin, and heparan sulfate binding reduce in vivo tissue transduction and toxicity. Hum Gene Ther 2006, 17:264-279.
39. Doronin K., Shashkova E.V., May S.M., Hofherr S.E., Barry M.A. Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther 2009, 20:975-988.
40. Breidenbach M., Rein D.T., Wang M., Nettelbeck D.M., Hemminki A., Ulasov I., et al. Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy. Hum Gene Ther 2004, 15:509-518.
41. Vigne E., Dedieu J.F., Brie A., Gillardeaux A., Briot D., Benihoud K., et al. Genetic manipulations of adenovirus type 5 fiber resulting in liver tropism attenuation. Gene Ther 2003, 10:153-162.
42. Einfeld D.A., Schroeder R., Roelvink P.W., Lizonova A., King C.R., Kovesdi I., et al. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol 2001, 75:11284-11291.
43. Croyle M.A., Chirmule N., Zhang Y., Wilson J.M. "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol 2001, 75:4792-4801.
44. Eto Y., Yoshioka Y., Mukai Y., Okada N., Nakagawa S. Development of PEGylated adenovirus vector with targeting ligand. Int J Pharm 2008, 354:3-8.
45. Natsume A., Mizuno M., Ryuke Y., Yoshida J. Cationic liposome conjugation to recombinant adenoviral vector reduces viral antigenicity. Jpn J Cancer Res 2000, 91:363-367.
46. Yotnda P., Chen D.H., Chiu W., Piedra P.A., Davis A., Templeton N.S., et al. Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther 2002, 5:233-241.